| http://www.w3.org/ns/prov#value | - Two recently marketed anti-obesity agents, Xenical (Orlistat/Roche) and Meridia (Reductil/BASF) exhibit only modest efficacy (Orlistat) and have safety/side effect concerns (Orlistat-gastrointestinal and Meridia-hypertensive effects, respectively), thus limiting their use. [0016] Thus, although there are a variety of anti-atherosclerosis, obesity and diabetes therapies, there is a continuing need
|
